
Immutep Ltd (IMMP) Stock Forecast & Price Target
Immutep Ltd (IMMP) Analyst Ratings
Bulls say
Immutep is positioning itself as a leader in the LAG-3 immunotherapy space with a strong pipeline and strategic collaborations. The company's financials are strong, with a cash balance of $60 million and a debt-free balance sheet. Immutep has also secured funding from government grants and has collaborations with major pharmaceutical companies, providing additional financial support for its research and development efforts. Overall, Immutep has a promising outlook as a potential leader in LAG-3 related immunotherapies, with a strong drug candidate, experienced leadership team, and solid financial foundation.
Bears say
Immutep is facing significant hurdles in its Phase three clinical trials, as KOLs are skeptical about the durability and OS trajectory of efti and note the concerns surrounding larger, randomized NSCLC datasets. Furthermore, while adenocarcinoma is the most common type of NSCLC, it develops in the smaller airways and is usually found in areas of chronic inflammation, leading to doubts about efti's effectiveness in treating this subtype. Additionally, the company is facing competition in the rapidly evolving field of targeted therapies, with only one other company exploring a comparable LAG-3 agonist approach, and a majority of companies focused on LAG-3 antagonists. With a risky and capital-intensive drug development process, Immutep's current Phase three trial for NSCLC poses significant binary outcome risk.
This aggregate rating is based on analysts' research of Immutep Ltd and is not a guaranteed prediction by Public.com or investment advice.
Immutep Ltd (IMMP) Analyst Forecast & Price Prediction
Start investing in Immutep Ltd (IMMP)
Order type
Buy in
Order amount
Est. shares
0 shares